MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more
Market Cap & Net Worth: MaxCyte Inc (MXCT)
MaxCyte Inc (NASDAQ:MXCT) has a market capitalization of $85.34 Million ($85.34 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19288 globally and #7107 in its home market, demonstrating a 3.90% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MaxCyte Inc's stock price $0.80 by its total outstanding shares 106674011 (106.67 Million).
MaxCyte Inc Market Cap History: 2021 to 2026
MaxCyte Inc's market capitalization history from 2021 to 2026. Data shows change from $1.09 Billion to $85.34 Million (-48.30% CAGR).
Index Memberships
MaxCyte Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #532 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1772 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.01% | #237 of 263 |
Weight: MaxCyte Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MaxCyte Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MaxCyte Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.49x
MaxCyte Inc's market cap is 11.49 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.09 Billion | $33.89 Million | -$19.08 Million | 32.07x | N/A |
| 2022 | $582.44 Million | $44.26 Million | -$23.57 Million | 13.16x | N/A |
| 2023 | $501.37 Million | $41.29 Million | -$37.92 Million | 12.14x | N/A |
| 2024 | $443.76 Million | $38.63 Million | -$41.05 Million | 11.49x | N/A |
Competitor Companies of MXCT by Market Capitalization
Companies near MaxCyte Inc in the global market cap rankings as of March 19, 2026.
Key companies related to MaxCyte Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
MaxCyte Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, MaxCyte Inc's market cap moved from $1.09 Billion to $ 85.34 Million, with a yearly change of -48.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $85.34 Million | -48.39% |
| 2025 | $165.34 Million | -62.74% |
| 2024 | $443.76 Million | -11.49% |
| 2023 | $501.37 Million | -13.92% |
| 2022 | $582.44 Million | -46.42% |
| 2021 | $1.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of MaxCyte Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $85.34 Million USD |
| MoneyControl | $85.34 Million USD |
| MarketWatch | $85.34 Million USD |
| marketcap.company | $85.34 Million USD |
| Reuters | $85.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.